NDAORALCAPSULE
Approved
Jan 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
EVOXAC (cevimeline hydrochloride) by Aurobindo Pharma is clinical pharmacology pharmacodynamics cevimeline is a cholinergic agonist which binds to muscarinic receptors. First approved in 2000.
Drug data last refreshed 7h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVOXAC (cevimeline hydrochloride) is an oral small-molecule cholinergic agonist approved in 2000 for treating xerostomia (dry mouth) in patients with Sjögren's Syndrome. It works by binding to muscarinic receptors to stimulate salivary gland secretion and restore moisture to oral tissues. Clinical data showed 76% of patients on 30 mg three times daily reported global improvement in dry mouth symptoms versus 35% on placebo.
$0.001BPart D
LOE ApproachingDeclining
Product is in late-stage life cycle with minimal commercial momentum; brand team likely operating in maintenance/defense mode with reduced headcount expectations.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Cevimeline is a cholinergic agonist which binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands and increase tone of the smooth muscle in the gastrointestinal and…
Worked on EVOXAC at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.